Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingEarly Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingFecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingAutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingStem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingStudy of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingExpanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingIltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
  • Go to the previous page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 32
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us